Troels Korshøj Bergmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Troels Korshøj Bergmann has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Kim Brøsen
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark
12 shared publications - Per Damkier
Department of Clinical Research, Faculty of Health Sciences University of Southern Denmark Odense Denmark
10 shared publications - Christine Elizabeth Staatz
School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia
7 shared publications - Werner Vach
Center for Muscle and Joint Health, Department of Sport Sciences and Clinical Biomechanics, University of Southern Denmark, Odense M, Denmark
6 shared publications - Tore Bjerregaard Stage
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark
5 shared publications - Henrik Gréen
Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden
4 shared publications
Latest Publications
- Open Access
- 23 June 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (1) , e70056
Limited Sampling Strategies to Predict Mycophenolic Acid and Tacrolimus Area Under the Concentration–Time Curve in Steroid‐Free Kidney Transplant Patients
This study aimed to develop limited sampling strategies to predict oral mycophenolic acid (MPA) exposure from one to three blood samples in stable steroid‐free kidney‐transplanted patients and assess if the same scheme could predict tacrolimus exposure. Additionally, we aimed to validate existing strategies, and to describe the pharmacokinetics of MPA and its inactive metabolite, MPA‐glucuronide (MPAG), in our cohort. We analysed data from dense pharmacokinetic sampling from 15 steroid‐free kidney‐transplanted patients, which were prospectively enrolled as part of larger cohort. Drug concentration was analysed in plasma (MPA, MPAG) or in whole blood (tacrolimus) using LC–MS. Exposure (AUC0‐12h) was based on non‐compartmental analysis (MPA, MPAG) or model‐derived (tacrolimus). Limited sampling strategies were developed using multiple stepwise linear regression analysis and evaluated for bias and imprecision and using Bland–Altman analysis. Median AUC0‐12h was 31.2 μg/mL·h, 346.6 μg/mL·h and 81.9 ng/mL·h for MPA, MPAG and tacrolimus, respectively. Limited sampling strategies incorporating measurements at C0 and C1.5, or at C0, C0.5 and C1.5 could predict MPA and tacrolimus AUC0‐12h with low (< 15%) bias and imprecision. None of the previous strategies could adequately predict MPA AUC0‐12h. Limited sampling strategies for MPA and tacrolimus can potentially replace full pharmacokinetic profiling in steroid‐free kidney transplant patients. External validation is needed before implementation.Summary: Kidney‐transplanted patients are treated with immunosuppressive drugs throughout the lifespan of the transplanted organ. In this study, we aimed to derive mathematical equations that can simultaneously predict the total oral drug exposure of two of these drugs (tacrolimus and mycophenolate mofetil) based on few blood samples. We analysed drug concentration in blood samples from 15 patients, calculated their exposure and assessed how accurately the mathematical equations could predict the exposure. We could predict the total drug exposure from two or three samples, and these equations can be used in future research and in the clinic to ensure proper immunosuppressive levels.
- 23 June 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (1) , e70056
Open AccessLimited Sampling Strategies to Predict Mycophenolic Acid and Tacrolimus Area Under the Concentration–Time Curve in Steroid‐Free Kidney Transplant Patients
This study aimed to develop limited sampling strategies to predict oral mycophenolic acid (MPA) exposure from one to three blood samples in stable steroid‐free kidney‐transplanted patients and assess if the same scheme could predict tacrolimus exposure. Additionally, we aimed to validate existing strategies, and to describe the pharmacokinetics of MPA and its inactive metabolite, MPA‐glucuronide (MPAG), in our cohort. We analysed data from dense pharmacokinetic sampling from 15 steroid‐free kidney‐transplanted patients, which were prospectively enrolled as part of larger cohort. Drug concentration was analysed in plasma (MPA, MPAG) or in whole blood (tacrolimus) using LC–MS. Exposure (AUC0‐12h) was based on non‐compartmental analysis (MPA, MPAG) or model‐derived (tacrolimus). Limited sampling strategies were developed using multiple stepwise linear regression analysis and evaluated for bias and imprecision and using Bland–Altman analysis. Median AUC0‐12h was 31.2 μg/mL·h, 346.6 μg/mL·h and 81.9 ng/mL·h for MPA, MPAG and tacrolimus, respectively. Limited sampling strategies incorporating measurements at C0 and C1.5, or at C0, C0.5 and C1.5 could predict MPA and tacrolimus AUC0‐12h with low (< 15%) bias and imprecision. None of the previous strategies could adequately predict MPA AUC0‐12h. Limited sampling strategies for MPA and tacrolimus can potentially replace full pharmacokinetic profiling in steroid‐free kidney transplant patients. External validation is needed before implementation.Summary: Kidney‐transplanted patients are treated with immunosuppressive drugs throughout the lifespan of the transplanted organ. In this study, we aimed to derive mathematical equations that can simultaneously predict the total oral drug exposure of two of these drugs (tacrolimus and mycophenolate mofetil) based on few blood samples. We analysed drug concentration in blood samples from 15 patients, calculated their exposure and assessed how accurately the mathematical equations could predict the exposure. We could predict the total drug exposure from two or three samples, and these equations can be used in future research and in the clinic to ensure proper immunosuppressive levels.
- Open Access
- 10 August 2024
- Published by Wiley
Experiences from the Initial Three Years of Introducing the BPS/MSC Prescribing Safety Assessment for Danish Junior Doctors
Aim: The British Pharmacological Society and UK Medical Schools Council Prescription Safety Assessment (BPS/MSC PSA) is an electronic platform developed for assessing the prescription skills of medical students. Our aim was to investigate the feasibility of the PSA in addressing prescribing competencies among junior doctors in a hospital setting. Methods: The Department of Clinical Pharmacology at Odense University Hospital (OUH) established a Danish translated program using the BPS/MSC PSA platform. We launched a formal three year program in 2021, potentially assessing all first-year doctors at OUH and Esbjerg Regional Hospital. Participation was mandatory, followed by a survey (not mandatory). Results: During the period of 2021 to 2023 n= 364 doctors were invited, from which n=246 participated. The compliance rate increased from 38% in 2021 to 88% in 2023. The mean assessment score (points normalized to percentage) across n=246 participants was 71%, and 94% achieved a score of at least 50%. The survey was distributed to n=402 with 90 responses (22%) from which n=71 completed the questionnaire. Of these, 64% stated that the purpose with the assessment was clear. The two questions about difficulty level and the number of questions had similar evaluations. The majority of respondents found that the questions were of clinical relevance. Conclusion: It is feasible to translate and implement the PSA in a Danish hospital setting. The program provides insight into the prescribing competencies of junior doctors and the participants are generally positive.
- 10 August 2024
- Published by Wiley
Open AccessExperiences from the Initial Three Years of Introducing the BPS/MSC Prescribing Safety Assessment for Danish Junior Doctors
Aim: The British Pharmacological Society and UK Medical Schools Council Prescription Safety Assessment (BPS/MSC PSA) is an electronic platform developed for assessing the prescription skills of medical students. Our aim was to investigate the feasibility of the PSA in addressing prescribing competencies among junior doctors in a hospital setting. Methods: The Department of Clinical Pharmacology at Odense University Hospital (OUH) established a Danish translated program using the BPS/MSC PSA platform. We launched a formal three year program in 2021, potentially assessing all first-year doctors at OUH and Esbjerg Regional Hospital. Participation was mandatory, followed by a survey (not mandatory). Results: During the period of 2021 to 2023 n= 364 doctors were invited, from which n=246 participated. The compliance rate increased from 38% in 2021 to 88% in 2023. The mean assessment score (points normalized to percentage) across n=246 participants was 71%, and 94% achieved a score of at least 50%. The survey was distributed to n=402 with 90 responses (22%) from which n=71 completed the questionnaire. Of these, 64% stated that the purpose with the assessment was clear. The two questions about difficulty level and the number of questions had similar evaluations. The majority of respondents found that the questions were of clinical relevance. Conclusion: It is feasible to translate and implement the PSA in a Danish hospital setting. The program provides insight into the prescribing competencies of junior doctors and the participants are generally positive.
- 26 January 2024
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 134 (4) , 485-497
Review of clinical pharmacokinetics and pharmacodynamics of clonidine as an adjunct to opioids in palliative care
Clonidine is an α‐adrenoceptor agonist acting on receptors in the brain and peripheral tissues, leading to a reduction in sympathetic outflow and release of certain neurotransmitters. Clonidine has multiple uses across various medical conditions. One of its uses is as adjuvant to anaesthetic and analgesic agents specially opioids, mostly administered through intravenous and epidural routes. The opioids, effective in cancer pain management, are associated with various side effects such as sedation, pruritus, constipation, nausea, respiratory depression, tolerance and dependence. Combination of clonidine with opioids seems to help to achieve better pain management and less need of opioids. Use of clonidine in palliative care has been less common, but it is gradually gaining recognition for its potential benefits in managing symptoms like cancer pain and agitation. This combination approach has been explored in palliative care settings, including cancer pain and agitation, where patients experience complex and refractory symptoms. It seems to be well tolerated and gives better symptom relief. The available literature on clonidine's use in cancer pain and agitation management, especially in subcutaneous form, is limited and outdated. Therefore, the optimal dosing, safety profile and overall effectiveness of subcutaneous clonidine requires further exploration through prospective research studies.
- 26 January 2024
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 134 (4) , 485-497
Review of clinical pharmacokinetics and pharmacodynamics of clonidine as an adjunct to opioids in palliative care
Clonidine is an α‐adrenoceptor agonist acting on receptors in the brain and peripheral tissues, leading to a reduction in sympathetic outflow and release of certain neurotransmitters. Clonidine has multiple uses across various medical conditions. One of its uses is as adjuvant to anaesthetic and analgesic agents specially opioids, mostly administered through intravenous and epidural routes. The opioids, effective in cancer pain management, are associated with various side effects such as sedation, pruritus, constipation, nausea, respiratory depression, tolerance and dependence. Combination of clonidine with opioids seems to help to achieve better pain management and less need of opioids. Use of clonidine in palliative care has been less common, but it is gradually gaining recognition for its potential benefits in managing symptoms like cancer pain and agitation. This combination approach has been explored in palliative care settings, including cancer pain and agitation, where patients experience complex and refractory symptoms. It seems to be well tolerated and gives better symptom relief. The available literature on clonidine's use in cancer pain and agitation management, especially in subcutaneous form, is limited and outdated. Therefore, the optimal dosing, safety profile and overall effectiveness of subcutaneous clonidine requires further exploration through prospective research studies.
- Top Cited PapersOpen Access
- 27 September 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 133 (4) , 391-396
BCPT 2023 policy for experimental and clinical studies
The manuscript is an updated version of the previously published "BCPT policy for experimental and clinical studies" from 2021.
- 27 September 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 133 (4) , 391-396
Top Cited PapersOpen AccessBCPT 2023 policy for experimental and clinical studies
The manuscript is an updated version of the previously published "BCPT policy for experimental and clinical studies" from 2021.
- 12 May 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 133 (1) , 3-5
ChatGPT: First glance from a perspective of clinical pharmacology
- 12 May 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 133 (1) , 3-5
ChatGPT: First glance from a perspective of clinical pharmacology
- Open Access
- 23 March 2023
- Published by Wiley
ChatGPT: First Glance from a Perspective of Clinical Pharmacology
ChatGPT: First Glance from a Perspective of Clinical PharmacologyAuthors: Julie Rudbech Krumborg1,2, Nicolaj Mikkelsen1,2, Per Damkier1,2, Zandra Nymand Ennis1,2, Daniel Pilsgaard Henriksen1,2, Mads Lillevang-Johansen1,2, Sidsel Arnspang Pedersen1,2, Troels K Bergmann1,31. Department of Clinical Pharmacology, Odense University Hospital, Denmark2. Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Denmark3. Department of Regional Health Research, University of Southern Denmark, Esbjerg, DenmarkCorresponding author: Julie Rudbech Krumborg: Julie.Rudbech.Krumborg@rsyd.dkKeywords : Artificial intelligence, Clinical Pharmacology, Drug Information Services, evidence-based medicine, Medical WritingConflict of interest statement: The authors state no conflicts of interest
- 23 March 2023
- Published by Wiley
Open AccessChatGPT: First Glance from a Perspective of Clinical Pharmacology
ChatGPT: First Glance from a Perspective of Clinical PharmacologyAuthors: Julie Rudbech Krumborg1,2, Nicolaj Mikkelsen1,2, Per Damkier1,2, Zandra Nymand Ennis1,2, Daniel Pilsgaard Henriksen1,2, Mads Lillevang-Johansen1,2, Sidsel Arnspang Pedersen1,2, Troels K Bergmann1,31. Department of Clinical Pharmacology, Odense University Hospital, Denmark2. Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Denmark3. Department of Regional Health Research, University of Southern Denmark, Esbjerg, DenmarkCorresponding author: Julie Rudbech Krumborg: Julie.Rudbech.Krumborg@rsyd.dkKeywords : Artificial intelligence, Clinical Pharmacology, Drug Information Services, evidence-based medicine, Medical WritingConflict of interest statement: The authors state no conflicts of interest
- 9 December 2022
- Published by Wolters Kluwer Health in Pain
- Vol. 164 (7) , 1502-1511
Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer
Paclitaxel-induced peripheral neuropathy (PIPN) is a barrier to effective cancer treatment and impacts quality of life among patients with cancer. We used a translational approach to assess the utility of neurofilament light chain (NFL) as a biomarker of PIPN in a human cell model and in patients with ovarian cancer. We measured NFL in medium from human induced pluripotent stem cell–derived sensory neurons (iPSC-SNs) exposed to paclitaxel. Serum NFL (sNFL) levels were quantified in 190 patients with ovarian cancer receiving paclitaxel/carboplatin chemotherapy at baseline and after each of the following 2 or 6 cycles. Adverse outcomes related to PIPN were retrospectively obtained, and Cox regression model was performed with different sNFL cut-offs after first cycle. The apparent elimination half-life of sNFL was estimated in patients who discontinued paclitaxel. Paclitaxel neurotoxicity in iPSC-SNs was accompanied by NFL release in a concentration-dependent manner (P < 0.001, analysis of variance). Serum NFL levels increased substantially in patients during paclitaxel/carboplatin chemotherapy with considerable interindividual variability. Patients with sNFL >150 pg/mL after first cycle had increased risk to discontinue paclitaxel early (unadjusted HR: 2.47 [95% CI 1.16-5.22], adjusted HR: 2.25 [95% CI: 0.88-5.79]). Similar trends were shown for risk of severe PIPN and paclitaxel dose reduction because of PIPN. The median elimination half-life of sNFL was 43 days (IQR 27-82 days). Neurofilament light chain constitutes an objective biomarker of neurotoxicity in iPSC-SNs and in ovarian cancer patients with high sNFL predicting PIPN-related adverse outcomes. If prospectively validated, NFL can be used to study PIPN and may guide clinical decision making and personalize treatment with paclitaxel.
- 9 December 2022
- Published by Wolters Kluwer Health in Pain
- Vol. 164 (7) , 1502-1511
Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer
Paclitaxel-induced peripheral neuropathy (PIPN) is a barrier to effective cancer treatment and impacts quality of life among patients with cancer. We used a translational approach to assess the utility of neurofilament light chain (NFL) as a biomarker of PIPN in a human cell model and in patients with ovarian cancer. We measured NFL in medium from human induced pluripotent stem cell–derived sensory neurons (iPSC-SNs) exposed to paclitaxel. Serum NFL (sNFL) levels were quantified in 190 patients with ovarian cancer receiving paclitaxel/carboplatin chemotherapy at baseline and after each of the following 2 or 6 cycles. Adverse outcomes related to PIPN were retrospectively obtained, and Cox regression model was performed with different sNFL cut-offs after first cycle. The apparent elimination half-life of sNFL was estimated in patients who discontinued paclitaxel. Paclitaxel neurotoxicity in iPSC-SNs was accompanied by NFL release in a concentration-dependent manner (P < 0.001, analysis of variance). Serum NFL levels increased substantially in patients during paclitaxel/carboplatin chemotherapy with considerable interindividual variability. Patients with sNFL >150 pg/mL after first cycle had increased risk to discontinue paclitaxel early (unadjusted HR: 2.47 [95% CI 1.16-5.22], adjusted HR: 2.25 [95% CI: 0.88-5.79]). Similar trends were shown for risk of severe PIPN and paclitaxel dose reduction because of PIPN. The median elimination half-life of sNFL was 43 days (IQR 27-82 days). Neurofilament light chain constitutes an objective biomarker of neurotoxicity in iPSC-SNs and in ovarian cancer patients with high sNFL predicting PIPN-related adverse outcomes. If prospectively validated, NFL can be used to study PIPN and may guide clinical decision making and personalize treatment with paclitaxel.
- Open Access
- 8 September 2022
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 131 (5) , 325-346
DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview
Background: In clinical oncology, systemic 5‐fluorouracil (5‐FU) and its oral pro‐drugs are used to treat a broad group of solid tumours. Patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency are at elevated risk of toxicity if treated with standard doses of 5‐FU. DPYD genotyping and measurements of plasma uracil concentration (DPD phenotyping) can be applied as tests for DPD deficiency. In April 2020, the European Medicines Agency recommended pre‐treatment DPD testing to reduce the risk of 5‐FU‐related toxicity.Objectives: The objective of this study is to present the current evidence for DPD testing in routine oncological practice.Methods: Two systematic literature searches were performed following the PRISMA guidelines. We identified studies examining the possible benefit of DPYD genotyping or DPD phenotyping on the toxicity risk.Findings: Nine and 12 studies met the criteria for using DPYD genotyping and DPD phenotyping, respectively.Conclusions: The evidence supporting either DPYD genotyping or DPD phenotyping as pre‐treatment tests to reduce 5‐FU toxicity is poor. Further evidence is still needed to fully understand and guide clinicians to dose by DPD activity.
- 8 September 2022
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 131 (5) , 325-346
Open AccessDPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview
Background: In clinical oncology, systemic 5‐fluorouracil (5‐FU) and its oral pro‐drugs are used to treat a broad group of solid tumours. Patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency are at elevated risk of toxicity if treated with standard doses of 5‐FU. DPYD genotyping and measurements of plasma uracil concentration (DPD phenotyping) can be applied as tests for DPD deficiency. In April 2020, the European Medicines Agency recommended pre‐treatment DPD testing to reduce the risk of 5‐FU‐related toxicity.Objectives: The objective of this study is to present the current evidence for DPD testing in routine oncological practice.Methods: Two systematic literature searches were performed following the PRISMA guidelines. We identified studies examining the possible benefit of DPYD genotyping or DPD phenotyping on the toxicity risk.Findings: Nine and 12 studies met the criteria for using DPYD genotyping and DPD phenotyping, respectively.Conclusions: The evidence supporting either DPYD genotyping or DPD phenotyping as pre‐treatment tests to reduce 5‐FU toxicity is poor. Further evidence is still needed to fully understand and guide clinicians to dose by DPD activity.
- Open Access
- 2 October 2021
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 130 (1) , 93-102
No significant influence of OCT1 genotypes on the pharmacokinetics of morphine in adult surgical patients
We investigated the impact of genetic variants in OCT1 (SLC22A1) on morphine, morphine‐3‐glucuronide (M3G) and morphine‐6‐glucuronide (M6G) pharmacokinetics in adult patients scheduled for major surgery. Blood samples were taken before and 5, 10, 15, 30, 45, 60 and 90 min after a bolus of morphine (0.15 mg/kg). Patients were genotyped for the genetic variants (rs12208357, rs34059508, rs72552763 and rs34130495) in OCT1.Eighty‐six patients completed the trial. The mean difference (95% confidence interval) for dose adjusted morphine, M3G and M6G AUC was 0.9 (−0.7–2.4), −5.9 (−11.8 to −0.03) and −1.1 (−2.5–0.4) h/L*10−6, respectively, in patients with two reduced function alleles compared to patients with no reduced function alleles in OCT1. Accordingly, the (AUCM3G/Dose)/(AUCmorphine/Dose) and (AUCM6G/Dose)/(AUCmorphine/Dose) ratio was reduced, −1.8 (−3.2 to −0.4) and −0.4 (−0.7 to −0.03), respectively, when comparing the same groups. OCT1 variants had no influence on the experience of pain, adverse events or the number of PCA doses used. In conclusion, genetic variants in OCT1 had a small and clinically unimportant impact on the exposure of morphine after intravenous administration. Our results do not support pre‐emptive genotyping for OCT1 prior to morphine administration in patients scheduled for major surgery.
- 2 October 2021
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 130 (1) , 93-102
Open AccessNo significant influence of OCT1 genotypes on the pharmacokinetics of morphine in adult surgical patients
We investigated the impact of genetic variants in OCT1 (SLC22A1) on morphine, morphine‐3‐glucuronide (M3G) and morphine‐6‐glucuronide (M6G) pharmacokinetics in adult patients scheduled for major surgery. Blood samples were taken before and 5, 10, 15, 30, 45, 60 and 90 min after a bolus of morphine (0.15 mg/kg). Patients were genotyped for the genetic variants (rs12208357, rs34059508, rs72552763 and rs34130495) in OCT1.Eighty‐six patients completed the trial. The mean difference (95% confidence interval) for dose adjusted morphine, M3G and M6G AUC was 0.9 (−0.7–2.4), −5.9 (−11.8 to −0.03) and −1.1 (−2.5–0.4) h/L*10−6, respectively, in patients with two reduced function alleles compared to patients with no reduced function alleles in OCT1. Accordingly, the (AUCM3G/Dose)/(AUCmorphine/Dose) and (AUCM6G/Dose)/(AUCmorphine/Dose) ratio was reduced, −1.8 (−3.2 to −0.4) and −0.4 (−0.7 to −0.03), respectively, when comparing the same groups. OCT1 variants had no influence on the experience of pain, adverse events or the number of PCA doses used. In conclusion, genetic variants in OCT1 had a small and clinically unimportant impact on the exposure of morphine after intravenous administration. Our results do not support pre‐emptive genotyping for OCT1 prior to morphine administration in patients scheduled for major surgery.